Merck & Company, Inc. · NYSE:MRK
Merck & — Investor Day (June 2022)
32 slides from Merck &'s investor day presentation, Jun 7, 2022
Slide 1: Merck ASCO Investor Event
PRESENT Merck ASCO Investor Event June 7, 2022
Slide 2: Presenters
Presenters Dr. Dean Li Dr. Eliav Barr Dr. Eric H. Rubin Jannie Oosthuizen President, Merck SVP, Head of Global SVP, Oncology Early President, Human Health Research Laboratories Clinical Development & Development U.S. Chief Medical Officer 2
Slide 3: Agenda
Agenda Opening | Dr. Dean Li ASCO 2022 Highlights | Dr. Eliav Barr Pipeline Update | Dr. Eric H. Rubin Commercial Update | Jannie Oosthuizen Closing | Dr. Dean Li Q&A 3
Slide 4: Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA
Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA This presentation of Merck & Co., Inc., Rahway, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These stateme
Slide 5: Dr. Dean Li
Dr. Dean Li President, Merck Research Laboratories
Slide 6: Transforming the treatment of cancer with industry's broadest oncology development program
Transforming the treatment of cancer with industry’s broadest oncology development program >1,750 >120 Ongoing clinical trials KEYTRUDA trials in earlier stages of disease and lines of therapy Oncology >1,300 Development >50 Combination trials Business development Program transactions in 2021 >100 >
Slide 7: Leading program aimed to further improve patient outcomes with greater than 80 potential new approvals through 2028
Leading program aimed to further improve patient outcomes with greater than 80 potential new approvals through 2028 <20% in a single ~40% in adjuvant and ~70% in combination or tumor type neoadjuvant coformulation Expand Extend Deepen into new tumor types into earlier lines of therapy response to KE
Slide 8: Dr. Eliav Barr
Dr. Eliav Barr SVP, Head of Global Clinical Development & Chief Medical Officer
Slide 9: Advancing our oncology pipeline since ASCO 2021 with a total of 12 FDA approvals
Advancing our oncology pipeline since ASCO 2021 with a total of 12 FDA approvals 6 Metastatic stage cancers Lung Breast KN-091 KN-3551 KN-522 5 Earlier-stage cancers Liver OLYMPIA KN-394 Skin KN-716 Renal KN-629 1 New molecular entity KN-564 Bladder KN-581 WELIREG KN-3612 Women’s cancers Prostate KN
Slide 10: ASCO 2022: continuing to generate evidence to help transform patient care
ASCO 2022: continuing to generate evidence to help transform patient care Key data presented since ASCO 2021 Impactful data at ASCO GU: AACR: ASCO GI: Demonstrating Longer-term follow-up data for KN-799 durable benefit (NSCLC), KN-224 (HCC), KN-022 (melanoma) KN-564 KEYVIBE-001 KN-590 and KN-651 (CR
Slide 11: KN-716: KEYTRUDA as an adjuvant treatment option in stage II melanoma
KN-716: clinically meaningful data supports KEYTRUDA as an adjuvant treatment option in stage II melanoma1 Distant metastasis-free survival KEYTRUDA reduced the risk of distant metastasis or death by 36% • DMFS data reinforces evidence for KEYTRUDA as adjuvant therapy in stage IIB and IIC melanoma1
Slide 12: Continue to make progress in earlier-stage settings
Continue to make progress in earlier-stage settings KN-522 (Neoadjuvant/adjuvant) KN-564 (Adjuvant) KN-091 (Adjuvant) TNBC RCC NSCLC EFS by Residual Cancer Burden at the time of surgery DMFS in the Intention to Treat Population DFS in the overall population Data cutoff date: March 23, 2021 Data cuto
Slide 13: First-time data for favezelimab in relapsed or refractory classical Hodgkin lymphoma
First-time data for favezelimab demonstrates potential in relapsed or refractory classical Hodgkin lymphoma Best target lesion change from baseline Favezelimab (anti-LAG-3) plus pembrolizumab demonstrated anti-tumor activity in PD-1 relapsed Target tumor reduction or refractory cHL patients in Phase
Slide 14: Long-term follow-up data confirm durable benefits of KEYTRUDA and WELIREG
Long-term follow-up data confirm durable benefits of KEYTRUDA and WELIREG across important indications KN-799 KN-224 WELIREG Stage III NSCLC 1L HCC VHL disease-associated RCC OS for cohort A (squamous and nonsquamous histology) OS Best % change from baseline in target lesion size +XX% YOY Data cutof
Slide 15: Dr. Eric H. Rubin
Dr. Eric H. Rubin SVP, Oncology Early Development
Slide 16: Advancing our diversified and innovative oncology pipeline with more than 20 novel mechanisms
Advancing our diversified and innovative oncology pipeline with more than 20 novel mechanisms Immuno-oncology/tumor Antibody-drug Redirected Molecularly targeted microenvironment conjugates cell killing therapies • Vibostolimab (anti-TIGIT) • Zilovertamab vedotin • Bi- and tri-specific T & NK • WELI
Slide 17: Vibostolimab is a novel anti-TIGIT candidate that builds on the foundation of KEYTRUDA
Vibostolimab is a novel anti-TIGIT candidate that builds on the foundation of KEYTRUDA KeyVibe- KeyVibe- KeyVibe- KeyVibe- 003 006 007 008 Stage III 1L mNSCLC 1L ES - Setting Inoperable 1L mNSCLC (PD-L1+) SCLC NSCLC 8 ongoing studies, including Development stage Ph 3 Ph 3 Ph 3 Ph 3 4 in Phase 3, eva
Slide 18: Targeted approach with additional coformulated checkpoint inhibitors in key tumor types
Targeted approach with additional coformulated checkpoint inhibitors in key tumor types to help address unmet needs favezelimab quavonlimab (anti-LAG-3) (anti-CTLA-4) PD-L1+ microsatellite-stable Setting classical Hodgkin lymphoma renal cell carcinoma colorectal cancer Ph 3 study planned in relapsed
Slide 19: WELIREG is well-positioned to expand to broader populations of patients with RCC
WELIREG is well-positioned to expand to broader populations of patients with RCC Potential additional indications in • Advancing studies in sporadic kidney cancer and other solid tumors kidney cancers, informed by our understanding of the Von Hippel-Lindau gene And more… • 4 pivotal Phase 3 clinical
Slide 20: Proven track record of developing precision medicine strategies
Proven track record of developing precision medicine strategies with the goal of identifying optimal treatment options for patients • 14 biomarker-driven indications across products to help identify patients eligible for treatment HNSCC Esophageal – First approval for an anti–PD-1 therapy with a bio
Slide 21: Emerging scientific technologies have the potential to profoundly improve patient outcomes
Emerging scientific technologies have the potential to profoundly improve patient outcomes Personalized DNA biopsies editing New technologies and our Imaging1 Sustaining Evading RNA proliferative growth signaling suppres- growing knowledge of tumor sors Deregulating Avoiding cellular immune energeti
Slide 22: Jannie Oosthuizen
Jannie Oosthuizen President, Human Health U.S.
Slide 23: Driving global growth across a broad portfolio of commercial assets
Driving global growth across a broad portfolio of commercial assets Significant progress from ASCO 2021 to ASCO 2022 Foundational cancer Market-leading TKI with multiple 40 treatment PARPi approved indications 46 Approved Indications 20 22 Tumor Types + MSI-H/dMMR and TMB-H Highly-selective First-in
Slide 24: Advancing a broad program, including targeting certain types of earlier-stage cancer
Advancing a broad program, including targeting certain types of earlier-stage cancer 2018–2021 2022 -2025 2026+ KN-054 KN-629 OlympiA KN-A18 KN-937 KN-242 KN-B15 LITESPARK- Melanoma cSCC Breast Cervical HCC TNBC MIBC 022 APPROVED APPROVED APPROVED RCC KN-866 LEAP-012 KN-756 KN-975 KN-057 KN-564
Slide 25: Successful launch of WELIREG for certain VHL disease-associated tumors
Successful launch of WELIREG for certain VHL disease-associated tumors with additional potential future opportunities First-in-class molecule • Approved in certain VHL disease-associated tumors with high unmet need Monotherapy • In VHL, most patients have multiple surgeries over many years; WELIREG
Slide 26: Expect to be leader in oncology driven by additional indications, earlier lines of therapy and new assets
Expect to be leader in oncology driven by additional indications, earlier lines of therapy and new assets and technologies >80 potential approvals expected through 2028… …enables Merck to sustain a strong growth trajectory in oncology Merck Number of indications Revenue 2021 2022 2023 2024 2025 2026
Slide 27: Dr. Dean Li
Dr. Dean Li President, Merck Research Labs
Slide 28: Shaping the future of oncology with our robust portfolio and pipeline
Shaping the future of oncology with our robust portfolio and pipeline Further establish KEYTRUDA as a foundational anti-PD-1 cancer treatment in monotherapy and in combination regimens Diversify through partnerships with Ladiratuzumab PARPi, VEGF TKI, HER2 TKI, LIV-1 ADC Vedotin (LV) Diversify throu
Slide 29: Dr. Roy Baynes
Dr. Roy RUDA® as Monoth ase 3 Studie: S Across a Ombination Suny; © Of Malignanci val Results les
Slide 30: Q&A
Q&A Dr. Dean Li Dr. Eliav Barr Dr. Eric H. Rubin Jannie Oosthuizen President, SVP, Head of Global SVP, Oncology Early President Human Merck Research Clinical Development & Development Health U.S. Laboratories Chief Medical Officer Dr. Scot Ebbinghaus Dr. Gregory Lubiniecki Peter Dannenbaum VP, Late-
Slide 31: Appendix
Appendix
Slide 32: Acronyms
Acronyms BRCAwt = BRCA wild-type ER = Estrogen receptor PARPi = poly-ADP ribose polymerase inhibitor cHL = Classical Hodgkin lymphoma ES = Extensive stage PFS = Progress free survival ccRCC = Clear cell renal cell carcinoma HCC = Hepatocellular carcinoma pNET = Primitive neuroectodermal tumor cCRT =